Luteolin as an adjuvant effectively enhanced the efficacy of adoptive tumor-specific CTLs therapy
The combination of luteolin and DC/tumor fusion vaccine-activated CTLs presents a novel approach for cancer treatment. As an adjuvant, luteolin downregulates YAP expression in tumor cells, enhancing CTL proliferation, cytotoxicity, and survival, thus improving tumor recognition and selective targeting. This strategy is promising for safe and effective tumor treatment.
Authors
- Shiguo Yuan (ORCID: https://orcid.org/0000-0003-3781-6786)
- Zhiheng Lai
- Kai Zheng (ORCID: https://orcid.org/0000-0001-9275-1239)
- W. Wang (ORCID: https://orcid.org/0009-0003-6192-1209)
- Leiyuan Chen
- Yanyang Pang (ORCID: https://orcid.org/0000-0002-6187-2852)
- Yujing Zhou (ORCID: https://orcid.org/0009-0008-7179-0755)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Hainan Provincial Hospital of Traditional Chinese Medicine (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1186/s12885-025-13831-8
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23